<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Adaptive Biotechnologies Corp — News on 6ix</title>
    <link>https://6ix.com/company/adaptive-biotechnologies-corp</link>
    <description>Latest news and press releases for Adaptive Biotechnologies Corp on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/adaptive-biotechnologies-corp" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683542b278dffbe2df0e1658.webp</url>
      <title>Adaptive Biotechnologies Corp</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp</link>
    </image>
    <item>
      <title>Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-to-report-first-quarter-2026-financial-results-on-may-5-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-to-report-first-quarter-2026-financial-results-on-may-5-2026</guid>
      <pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
      <description>SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to</description>
    </item>
    <item>
      <title>Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/slingshot-biosciences-appoints-jim-snook-as-senior-vice-president-global-sales</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/slingshot-biosciences-appoints-jim-snook-as-senior-vice-president-global-sales</guid>
      <pubDate>Thu, 05 Mar 2026 14:30:00 GMT</pubDate>
      <description>Slingshot Biosciences, the pioneer of synthetic cell mimic technology for flow cytometry controls, today announced the appointment of Jim Snook as Senior Vice President, Global Sales. In this role, Snook will lead the company&apos;s rapidly growing global sales organization, including management of Business Development Vice Presidents, Inside Sales and Distribution Managers, and Field Application Scientists.</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-reports-fourth-quarter-210500296</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-reports-fourth-quarter-210500296</guid>
      <pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
      <description>SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business,” sa</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-participate-upcoming-investor-210500090</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-participate-upcoming-investor-210500090</guid>
      <pubDate>Tue, 27 Jan 2026 21:05:00 GMT</pubDate>
      <description>SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science &amp; Diagnostic Tools Conference in Snowbird, UTParticipating on Tuesday, February 10, 2026TD Cowen 46th Annual</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-report-fourth-quarter-210500199</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-report-fourth-quarter-210500199</guid>
      <pubDate>Thu, 22 Jan 2026 21:05:00 GMT</pubDate>
      <description>SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-announces-preliminary-fourth-123000426</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-announces-preliminary-fourth-123000426</guid>
      <pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
      <description>Full year MRD revenue growth of 46% driven by clonoSEQ® testing volumeSEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was appr</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-present-44th-annual-jp-morgan-healthcare-conference-2025-12</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-present-44th-annual-jp-morgan-healthcare-conference-2025-12</guid>
      <pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
      <description>SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-announces-two-immune-receptor-licensing-agreements-pfizer</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-announces-two-immune-receptor-licensing-agreements-pfizer</guid>
      <pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
      <description>A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-participate-jefferies-fireside-chat-series-minimal-residual</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-participate-jefferies-fireside-chat-series-minimal-residual</guid>
      <pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
      <description>SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-showcases-leadership-hematology-oncology-mrd-new-clonoseqr</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-showcases-leadership-hematology-oncology-mrd-new-clonoseqr</guid>
      <pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
      <description>SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to</description>
    </item>
    <item>
      <title>Future in Tech Appoints Ed Moyle as Chief Information Security Officer</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/future-in-tech-appoints-ed-moyle-as-chief-information-security-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/future-in-tech-appoints-ed-moyle-as-chief-information-security-officer</guid>
      <pubDate>Tue, 02 Dec 2025 14:00:00 GMT</pubDate>
      <description>LOS ANGELES, December 02, 2025--FiT appoints cybersecurity leader Ed Moyle as CISO to advance enterprise security, strengthen product protection, and elevate industry presence.</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-announces-nearly-90-abstracts-featuring-clonoseqr-mrd</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-announces-nearly-90-abstracts-featuring-clonoseqr-mrd</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-reports-third-quarter-2025-financial-results-2025-11-05</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-reports-third-quarter-2025-financial-results-2025-11-05</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-report-third-quarter-2025-financial-results-november-5-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-report-third-quarter-2025-financial-results-november-5-2025</guid>
      <pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
      <description>SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-participate-morgan-stanley-23rd-annual-global-healthcare</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-participate-morgan-stanley-23rd-annual-global-healthcare</guid>
      <pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
      <description>SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-reports-second-quarter-2025-financial-results-2025-08-06</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-reports-second-quarter-2025-financial-results-2025-08-06</guid>
      <pubDate>Tue, 05 Aug 2025 04:00:00 GMT</pubDate>
      <description>SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-report-second-quarter-2025-financial-results-august-5-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-report-second-quarter-2025-financial-results-august-5-2025</guid>
      <pubDate>Tue, 15 Jul 2025 04:00:00 GMT</pubDate>
      <description>SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-and-flatiron-health-announce-integration-clonoseqr-mrd</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-and-flatiron-health-announce-integration-clonoseqr-mrd</guid>
      <pubDate>Tue, 01 Jul 2025 04:00:00 GMT</pubDate>
      <description>SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to</description>
    </item>
    <item>
      <title>Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/grindr-appoints-veteran-public-company-cfo-and-audit-committee-chair-chad-cohen-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/grindr-appoints-veteran-public-company-cfo-and-audit-committee-chair-chad-cohen-to-board-of-directors</guid>
      <pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
      <description>Cohen to serve as Chair of the Audit Committee WEST HOLLYWOOD, Calif.--(BUSINESS WIRE)-- Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™,</description>
    </item>
    <item>
      <title>Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers</title>
      <link>https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-highlights-new-data-2025-asco-annual-meeting-and-eha-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/adaptive-biotechnologies-corp/news/adaptive-biotechnologies-highlights-new-data-2025-asco-annual-meeting-and-eha-2025</guid>
      <pubDate>Fri, 30 May 2025 04:00:00 GMT</pubDate>
      <description>30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) --</description>
    </item>
  </channel>
</rss>